References
- Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. All Astm Proc. 2019;40(2):84–92.
- Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nature Rev Drug Disc. 2022;21(1):21–40.
- Alenius H, Sinkko H, Moitinho-Silva L, et al. The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases. Exp Dermatol. 2021;30(10):1517–1531. doi:10.1111/exd.14446
- Marini A, Aue N, Demessant AL, Salah S, Kerob D, Luger TA. Increased skin pH and transepidermal water loss may serve as predictor for atopic dermatitis flares. J Eur Acad Dermatol Venereol. 2023;37(2):e252–e4. doi:10.1111/jdv.18558
- Edslev SM, Agner T, Andersen PS. Skin microbiome in atopic dermatitis. Acta Derm Venereol. 2020;100(12):adv00164. doi:10.2340/00015555-3514
- Koh LF, Ong RY, Common JE. Skin microbiome of atopic dermatitis. Allergol Int. 2022;71(1):31–39. doi:10.1016/j.alit.2021.11.001
- Baldwin HE, Bhatia ND, Friedman A, Eng RM, Seite S. The role of cutaneous microbiota harmony in maintaining a functional skin barrier. J Drugs Dermatol. 2017;16(1):12–18.
- Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115–s23.
- Maliyar K, Sibbald C, Pope E, Gary Sibbald R. Diagnosis and management of atopic dermatitis: a review. Adv Skin Wound Care. 2018;31(12):538–550. doi:10.1097/01.ASW.0000547414.38888.8d
- Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176–1193. doi:10.1111/j.1468-3083.2012.04636.x
- Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi:10.1111/jdv.16892
- Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053–1101. doi:10.1111/1346-8138.15090
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi:10.1111/jdv.14891
- Maintz L, Bieber T, Simpson HD, Demessant-Flavigny AL. From skin barrier dysfunction to systemic impact of atopic dermatitis: implications for a precision approach in dermocosmetics and medicine. J Pers Med. 2022;12(6):893. doi:10.3390/jpm12060893
- Elias PM. Optimizing emollient therapy for skin barrier repair in atopic dermatitis. Ann Allergy Asthma Immunol. 2022;128(5):505–511. doi:10.1016/j.anai.2022.01.012
- Zhong Y, Samuel M, van Bever H, Tham EH. Emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis. Allergy. 2022;77(6):1685–1699. doi:10.1111/all.15116
- Zelenkova H, Kerob D, Salah S, Demessant-Flavigny A-L. Impact of daily use of emollient ‘plus’ on corticosteroid consumption in patients with atopic dermatitis: an open, randomized controlled study. Eur Acad Dermatol Venereol. 2023;37(Suppl 5):27–34. doi:10.1111/jdv.18947
- Seité S, Zelenkova H, Martin R. Clinical efficacy of emollients in atopic dermatitis patients - relationship with the skin microbiota modification. Clin Cosmet Investig Dermatol. 2017;10:25–33. doi:10.2147/CCID.S121910
- Magnolo N, Jaenicke T, Tsianakas A, et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: a randomized controlled trial. Eur Acad Dermatol Venereol. 2023;37(Suppl 5):18–26. doi:10.1111/jdv.18949
- Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann All Astm Immunol. 2018;121(3):340–347.
- Xu X, van Galen LS, Koh MJA, et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. Sci Rep. 2019;9(1):15990. doi:10.1038/s41598-019-51129-5
- Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30. doi:10.1016/j.jid.2016.07.012
- Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161. doi:10.2340/00015555-3511
- Cabout E, Eymere S, Launois R, et al. Cost-effectiveness of emollients in the prevention of relapse among French patients with atopic dermatitis. Acta Derm Venereol. 2021;101(7):adv00509. doi:10.2340/00015555-3873
- Cabout E, Eymere S, Launois R, Aslanian F, Taïeb C, Seité S. Cost effectiveness of emollients in the prevention of relapses in atopic dermatitis. Clin Cosm Inv Dermatol. 2020;13:987–996. doi:10.2147/CCID.S279233
- Severity scoring of atopic dermatitis: the SCORAD index. consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31. doi:10.1159/000247298
- Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949. doi:10.1111/j.1365-2133.1995.tb16953.x
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
- Hamann CR, Andersen YMF, Engebretsen KA, et al. The effects of season and weather on healthcare utilization among patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2018;32(10):1745–1753. doi:10.1111/jdv.15023
- Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159(6):1357–1363. doi:10.1111/j.1365-2133.2008.08836.x
- Volz T, Skabytska Y, Guenova E, et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol. 2014;134(1):96–104. doi:10.1038/jid.2013.291
- Gueniche A, Cathelineau AC, Bastien P, et al. Vitreoscilla filiformis biomass improves seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(8):1014–1015. doi:10.1111/j.1468-3083.2007.02508.x
- Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L. The clinical relevance and therapeutic benefit of established active ingredients incorporated into advanced foam vehicles: vehicle characteristics can influence and improve patient outcomes. J Drugs Dermatol. 2019;18(2s):s100–s7.
- Zeichner J, Seite S. From probiotic to prebiotic using thermal spring water. J Drugs Dermatol. 2018;17(6):657–662.
- Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–1192. doi:10.1126/science.1171700
- Findley K, Grice EA. The skin microbiome: a focus on pathogens and their association with skin disease. PLoS Pathog. 2014;10(10):e1004436. doi:10.1371/journal.ppat.1004436
- Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi:10.1101/gr.131029.111
- Al-Ghazzewi FH, Tester RF. Impact of prebiotics and probiotics on skin health. Benef Microbes. 2014;5(2):99–107. doi:10.3920/BM2013.0040